We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Prime Medicine Inc (PRME) USD0.00001

Sell:$7.96 Buy:$8.60 Change: $0.13 (1.54%)
Market closed |  Prices as at close on 23 February 2024 | Switch to live prices |
Change: $0.13 (1.54%)
Market closed |  Prices as at close on 23 February 2024 | Switch to live prices |
Change: $0.13 (1.54%)
Market closed |  Prices as at close on 23 February 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Prime Medicine, Inc. is a biotechnology company engaged in creating and delivering the gene editing therapies to patients. The Company is leveraging its prime editing platform, a gene editing technology, to develop a new class of differentiated, one-time genetic therapies. Designed to make only the right edit at the right position within a gene while minimizing unwanted deoxyribonucleic acid (DNA) modifications, Prime Editors have the potential to repair almost all types of genetic mutations and work in many different tissues, organs and cell types. Its Prime Editors have two main components that act together to edit DNA: a Prime Editor protein, having a Cas protein and a reverse transcriptase enzyme that may be fused together, and a pegRNA, that targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It is progressing a diversified portfolio of about 18 programs initially focused on genetic diseases.

Contact details

21 Erie Street
United States
+1 (617) 4650013

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$1.02 billion
Shares in issue:
119.72 million
United States
US dollar

Key personnel

  • Keith Gottesdiener
    President, Chief Executive Officer, Director
  • Andrew Anzalone
    Co-Founder, Head of Prime Editing Platform
  • David Liu
  • Allan Reine
    Chief Financial Officer
  • Meredith Goldwasser
    Senior Vice President - Strategy and Corporate Operations
  • Ann Lee
    Chief Technical Officer
  • Jeremy Duffield
    Chief Scientific Officer
  • Carman Alenson
    Principal Accounting Officer
  • Richard Brudnick
    Chief Business Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.